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Characterizing the genetic basis of innate immune
response in TLR4-activated human monocytes
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Benno Pu¨tz10,*, Veit Hornung3,* & Johannes Schumacher1,2,*
Toll-like receptors (TLRs) play a key role in innate immunity. Apart from their function in host
defense, dysregulation in TLR signalling can confer risk to autoimmune diseases, septic shock
or cancer. Here we report genetic variants and transcripts that are active only during TLR
signalling and contribute to interindividual differences in immune response. Comparing
unstimulated versus TLR4-stimulated monocytes reveals 1,471 expression quantitative trait
loci (eQTLs) that are unique to TLR4 stimulation. Among these we ﬁnd functional SNPs for
the expression of NEU4, CCL14, CBX3 and IRF5 on TLR4 activation. Furthermore, we show that
SNPs conferring risk to primary biliary cirrhosis (PBC), inﬂammatory bowel disease (IBD) and
celiac disease are immune response eQTLs for PDGFB and IL18R1. Thus, PDGFB and IL18R1
represent plausible candidates for studying the pathophysiology of these disorders in the
context of TLR4 activation. In summary, this study presents novel insights into the genetic
basis of the innate immune response and exempliﬁes the value of eQTL studies in the context
of exogenous cell stimulation.
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T
he innate immune system is the ﬁrst line of defense against
invading microorganisms. It is equipped with pattern
recognition receptors (PRRs) that have evolved to sense
conserved microbe-associated molecular patterns. Among other
PRR families, Toll-like receptors (TLRs) play a pivotal role in
antimicrobial defense, with TLR4 being one of the best-
characterized member. TLR4 detects lipopolysaccharide (LPS)
derived from Gram-negative bacteria and relays signal
transduction to induce pro-inﬂammatory gene expression1.
Apart from their antimicrobial function, TLRs also sense
endogenous molecules, known as damage-associated molecular
patterns2,3. Mutations and polymorphisms in TLR and TLR-
signalling genes have been shown to confer susceptibility to many
infectious and inﬂammatory diseases4,5.
Here we perform transcriptome proﬁling in puriﬁed mono-
cytes and genome-wide single-nucleotide polymorphism (SNP)-
genotyping in 137 healthy individuals to identify transcripts and
genetic variants that contribute to interindividual differences in
TLR4 signalling. This innovative approach provides new insights
into the genetic control of innate immune response.
Results
Expression proﬁling of unstimulated (baseline) and TLR4-
stimulated monocytes revealed 9,031 differentially expressed
transcripts at 90-min LPS exposure (Po8.7 10 07, Bonfer-
roni-corrected P valueo0.01; Supplementary Fig. 1a). A duration
of 90min was chosen to study a time point that covers the
primary wave of gene expression (independent of de novo protein
synthesis) with an informative set of differentially expressed genes
following PRR stimulation6. Among the most strongly
differentially expressed genes (mean log2 fold change 41),
pathway analyses revealed a signiﬁcant enrichment of genes
involved in PRR signalling and their respective outputs
(Supplementary Fig. 1b and Supplementary Data 1). Further
subcategorization of differentially expressed genes into subsets of
coexpressed genes allowed additional reﬁnement of the ascribed
signalling pathways to speciﬁc clusters (Supplementary Fig. 1c
and Supplementary Data 2).
For both conditions—baseline and TLR4 signalling—
expression quantitative trait loci (eQTL) analyses were performed
and a false discovery rate (FDR) of 0.01 was used to deﬁne eQTLs
(PBaselineo8.67 10 09, PLPSo7.35 10 09). To avoid under-
estimation of shared eQTLs between treated and untreated
monocytes, we additionally conducted a multivariate analysis of
variance (MANOVA)7 (PManovao1.76 10 09, FDR-corrected
P valueo0.01, Supplementary Fig. 2a,b). In addition, we
calculated the differential expression of baseline vs TLR4-
stimulated cells and performed eQTL analyses using an FDR of
0.01 (PDLPS/Baselineo4.33 10–10). In total, we identiﬁed 975 cis
(corresponding to 292 genes) and 496 trans eQTLs
(corresponding to 184 genes), which are unique to TLR4
stimulation (Fig. 1b, Supplementary Fig. 3), as well as 435 cis
(corresponding to 74 genes) and 17 trans eQTLs (corresponding
to 8 genes), when differential expression (DLPS/Baseline) was
considered (Supplementary Fig. 4). A complete list of all
signiﬁcant eQTLs (baseline, LPS, DLPS/baseline) is provided by
Supplementary Data 3–5.
Interestingly, analysing all eQTLs together (both cis and trans,
baseline, LPS, DLPS/baseline) revealed a signiﬁcant enrichment
for lysosome-associated pathways, such as lysosomal enzymes
and respective trafﬁcking components (Supplementary Fig. 5,
Supplementary Data 6). This is noteworthy, as lysosomes have
been shown to play pivotal roles in both sensing and effector
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Figure 1 | Experimental design of the study in human monocytes of 137
healthy male donors. (a) Overview of step-wise study design applied in
human monocytes. (b) Venn diagrams of eQTLs and corresponding
transcripts of baseline (Baseline) and LPS-treated (LPS) monocytes in cis
(left) and trans (right). Linear regression model was used for eQTL
mapping. MANOVA was used to determine shared eQTLs.
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Figure 2 | rs3749155 represents the strongest cis iQTL during TLR4
signalling. Allele-speciﬁc gene expression in untreated versus LPS-treated
monocytes is depicted as violin plots. The distribution of log2 expression is
shown on the left (blue: baseline, red: LPS) and log2 fold change on the right
(orange). The dashed lines indicate the regressions of the (D) gene
expression values versus genotype. Individuals are indicated by small tick
marks on the respective axes, with the group sizes per genotype indicated
on top of each plot. The shaded ranges correspond to the 25–75% quartiles
with the median indicated separately (analogous to a common boxplot).
The violin plots show that NEU4 is induced in carriers of allele T on LPS
exposure, whereas NEU4 expression is reduced in homozygotes of allele C.
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function of innate immune cells, our results suggest that there is a
genetic contribution to these pathways8,9. In the following we
focused on eQTLs unique to TLR4 signalling, both under absolute
and differential expression, and refer to them as immune
response eQTLs or iQTLs.
In line with the pathway analysis above, our strongest iQTL
(Supplementary Table 1) is represented by the SNP rs3749155 on
chromosome 2q37 and regulates the expression of neuraminidase
4 (NEU4), which belongs to a group of lysosomal neuraminidases
that catalyse the cleavage of sialic acids linked to glycoconju-
gates10. This iQTL is located in intron 3 of NEU4 and regulates
its expression in cis (PLPS¼ 3.44 10–44, Fig. 2). In the context
of innate immune signalling pathways, neuraminidases have been
shown to regulate the activity of TLRs at the posttranslational
level. For example, NEU1—the best-characterized
neuraminidase—promotes the cleavage of sialic acids from the
ectodomain of TLR4, which is a prerequisite for TLR activation11.
Although a similar effect on TLR4 has been observed for NEU4
(ref. 12), the relevance of NEU4 to innate immunity has been less
intensively studied so far. Our ﬁndings, however, suggest that
genetic variability in NEU4 strongly contributes to interindividual
differences in the innate immune response.
SNP rs1719126 on chromosome 17q12 is the most signiﬁcant
trans iQTL and additionally represents the third strongest cis
iQTL (Supplementary Table 1). In cis rs1719126 regulates the
expression of the chemokine (C-C motif) ligand 14 (CCL14) gene,
whose transcription start site (TSS) is 101 kb distant from
rs1719126 (PLPS¼ 5.80 10–30, Fig. 3a). Chip-seq data from
ENCODE13 revealed an RNA polymerase II binding site
overlapping rs1719126, which represents a potential mechanism
of CCL14 regulation (Supplementary Fig. 6). On the functional
level, CCL14 is a highly expressed chemokine, whose activity as a
chemotactic signal for pro-inﬂammatory cells is mainly regulated
by a proteolytic processing step14. Our data now reveal that
CCL14 is additionally regulated at the transcriptional level with
strong genetic determination.
In trans rs1719126 regulates the expression of the chromobox
protein homolog 3 (CBX3) gene on chromosome 7p15 (PLPS¼ 3.48
 10–28, Fig. 3b). We observed a strong correlation between
CCL14 and CBX3 expressions among our volunteers (r2¼ 0.79,
Fig. 3c), indicating that cis-modulation of CCL14 results in
differential expression of CBX3. While previous studies have found
that CBX3 acts as a heterochromatin protein15, a recent study has
shown that CBX3 directly regulates the expression and splicing of
many genes16. In particular, after cytokine exposure CBX3 is
speciﬁcally recruited to inﬂammatory genes16.
Next, we used differential gene expression on TLR4 stimulation
(DLPS/baseline) as an alternative quantitative trait to identify
iQTLs that are already present in unstimulated monocytes but
have additional allele-speciﬁc effects during immune response
(Supplementary Fig. 4). Among these, rs10239340 on chromo-
some 7q32 acts in cis on the expression of interferon 5 (IRF5) and
represents the most signiﬁcant iQTL (Supplementary Table 2).
In baseline monocytes, carriers of the T allele show elevated IRF5
Lo
g 2
 
e
xp
re
ss
io
n
Lo
g 2
 
e
xp
re
ss
io
n
5
6
7
8
9
10
11
−4
−2
0
2
4
CCL14
Basis/LPS Fold change
74 56 674 56 6
TT TC CC
rs1719126
TT TC CC
CBX3
74 56 6 74 56 6
Basis/LPS Fold change
6.5
7.0
7.5
8.0
8.5
9.0
−1.5
−1.0
−0.5
0.0
0.5
1.0
1.5
2.0
rs1719126
TT TC CC TT TC CC
5
6
7
8
9
10
11
Ex
pr
es
sio
n 
of
 C
BX
3 
(no
rm
ali
ze
d l
og
2)
6.5 7.0 7.5 8.0 8.5 9.0
Expression of CCL14 (normalized log2)
TT
TC
CC
r 2 = 0.79
Lo
g 2
 
fo
ld
 c
ha
ng
e
Lo
g 2
 
fo
ld
 c
ha
ng
e
Figure 3 | rs1719126 represents the strongest trans and the third strongest cis iQTL during TLR4 signalling. (a) In homozygous carriers of allele T,
CCL14 expression is induced on LPS exposure and reduced in homozygotes for the opposite allele. (b) The allele-speciﬁc expression of CBX3 is nearly
identical to that observed for CCL14. The same homozygous T carriers show an induction of CBX3 expression on LPS exposure, whereas a reduced
expression is observed in homozygotes for the opposite allele. (c) Correlation of CCL14 and CBX3 expressions on LPS exposure (r2¼0.79).Violin plots are
depicted as in Fig. 2.
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expression compared with carriers of the opposite allele
(PBaseline¼ 3.97 10–59). However, on TLR4 stimulation T-allele
carriers show an allele-speciﬁc downregulation of IRF5 (PDLPS/
Baseline¼ 1.63 10–35, Fig. 4). IRF5 represents a key pro-
inﬂammatory transcription factor for the expression of many
immune-relevant genes17. Thus, IRF5 expression differences
during TLR4 signalling probably affect pro-inﬂammatory
immune response at later time points.
eQTLs for the expression of IRF5 have been previously found
in unstimulated LCLs and whole-blood samples18,19. In LCLs we
observed an opposing directional eQTL effect18 compared with
monocytes. Here, carriers of the G allele showed elevated IRF5
expression compared with carriers of allele T. In contrast, in
whole-blood samples19 we studied rs10229001, which is in perfect
LD to our eQTL marker (r2¼ 1) and observed the same
expression effect as seen in monocytes. Thus—besides the
context speciﬁc eQTL effect on LPS stimulation—rs10239340
represents a cell-type-speciﬁc eQTL.
Recently lysozyme (LYZ) on chromosome 12q15 has been
described as a monocyte-speciﬁc master regulator eQTL20. In this
study, rs10784774 was identiﬁed as cis eQTL for LYZ and as trans
eQTL for 62 other genes under baseline condition. Analysis of
hotspots in our data conﬁrms LYZ as a master regulator
(Supplementary Fig. 7a). LYZ was allele-speciﬁcally regulated in
cis (PBaseline¼ 4.38 10–37) and a total of 108 different genes in
trans (Supplementary Fig. 7b and Supplementary Data 7). This
master regulator eQTL was also present in stimulated monocytes
(Supplementary Fig. 7). However, no LYZ-regulated transcript
showed a signiﬁcant differential expression on TLR4 stimulation,
indicating that this pathway does not play a prominent role in the
early phase of TLR4 signalling.
Finally, we tested whether SNPs that have been identiﬁed as
risk factors for common diseases represent iQTLs and used all
SNPs that have been deposited in the Catalog of Published
Genome-Wide Association Studies. This revealed many GWAS-
SNPs that are eQTLs under baseline and TLR4-signalling
condition (Supplementary Data 8) as well as GWAS-SNPs as
being active iQTLs only during TLR4 signalling.
The most signiﬁcant GWAS-iQTL represents rs968451 on
chromosome 22q13, which regulates the expression of the
platelet-derived growth factor beta polypeptide (PDGFB) gene in
cis. The expression of PDGFB is induced during TLR4 signalling
strongest for carriers of the common allele G (PLPS¼ 4.31 10–
12, PDLPS/Baseline¼ 6.09 10–12, Fig. 5a). SNP rs968451 is located
30 kb distant to the TSS of PDGFB and also confers risk for
primary biliary cirrhosis (PBC)21, a severe autoimmune liver
disease characterized by a destructive cholangitis. In this GWAS,
the authors favoured MAP3K7IP1 as being the risk-conferring
PBC gene at this locus21, which is located 125 kb distant to
rs968451. However, the testing of all transcripts within a 10-Mb
interval of rs968451 in our data set revealed that PDGFB is the
only transcript regulated by the PBC risk variant during TLR4
signalling (Fig. 5b).
Our data show that the PBC variant rs968451 regulates PDGFB
expression with reduced transcript levels in risk allele carriers.
This function is only active during TLR4 signalling, which ﬁts
pathophysiological concepts, according to which TLR signalling
confers PBC risk22. We therefore suggest PDGFB as a novel PBC
risk gene at this locus. Also, on the functional level PDGFB
represents a plausible PBC risk gene, given its involvement in the
induction of angiogenesis, a process that has been linked to the
pathophysiology of PBC23.
The second GWAS-iQTL concerns rs917997 on chromosome
2q12, which is 91 kb distant to the TSS of the interleukin 18
receptor 1 (IL18R1) gene and regulates its expression in cis.
Only during TLR4 signalling is the expression of IL18R1
induced in homozygous A carriers and reduced in homozygous
carriers of the opposite allele (PLPS¼ 3.10 10–9,
PDLPS/baseline¼ 5.99 10–11, Fig. 5c). Allele A of rs917997 has
been identiﬁed as a risk factor for inﬂammatory bowel disease
(IBD)24 and celiac disease25, both inﬂammatory diseases of the
intestine. However, based on GWAS data it was not possible to
favour a risk gene, because IL18R1 forms, together with the
interleukin receptor genes IL1R1, IL1R2, IL1RL1, IL1RL2 and
IL18RAP, a cluster at this locus. We tested whether these or other
nearby genes are also regulated by rs917997 during TLR4
signalling. Although not signiﬁcant, IL18RAP is additionally cis-
regulated within a 10-Mb interval of the risk variant
(PLPS¼ 1.8 10–4, Fig. 5d and Supplementary Fig. 8).
Our data show that rs917997 becomes functionally active only
during TLR4 signalling and thereby inﬂuences IL18R1 expression
and to lesser extent IL18RAP expression. IL18R1 and IL18RAP
form the heterodimeric IL18 receptor complex, which relays IL18-
dependent signal transduction to the NFkB-pathway26. As such,
IL18R1 and IL18RAP represent plausible risk genes for IBD and
celiac disease at this locus, particularly as alterations in IL18- and
TLR-mediated processes have been reported for both disorders27.
As for IRF5, an eQTL effect of rs917997 on the expression of
IL18RAP has been previously described in unstimulated whole-
blood samples28. In this study, opposing directional expression
effects compared with monocytes have been observed. Carriers of
allele G show elevated IL18RAP expression levels compared with
carriers of allele A. This further exempliﬁes that gene regulation
represents a complex cell–type- and context-speciﬁc process.
Whether cell-type-speciﬁc eQTLs are functionally more
susceptible to environmental inﬂuences, such as exogenous cell
stimulation, represents an interesting hypothesis. However, future
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Figure 4 | rs10239340 represents the strongest iQTL during TLR4
signalling that is also functionally active in baseline monocytes and
shows an additional regulatory effect on differential expression on LPS
exposure. Carriers of the T allele have elevated baseline IRF5 expression
compared with individuals carrying the G allele (left; blue violin plots). On
LPS exposure a robust downregulation of IRF5 proportional to the number of
T alleles is observed, whereas no differential regulation is seen in
homozygotes for the G allele (right; orange violin plots). Violin plots are
depicted as in Fig. 2.
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studies could test this hypothesis, as eQTL data for large numbers
of different cell types become increasingly available.
Recently two studies identiﬁed eQTLs under LPS stimulation
in primary human monocytes29 and dendritic cells30.
Comparison of our study with these studies showed a
signiﬁcant overlap between our data and those of Fairfax
et al.29 In all, 43 and 44% of our monocyte data under baseline
and LPS stimulation, respectively, were found to be genome-wide
signiﬁcant in Fairfax et al. (Supplementary Fig. 9a) and 55
(baseline) and 56% (LPS) of the data of Fairfax et al. showed
evidence of replication in our data set (Supplementary Fig. 9b).
Lee et al.30 used a targeted approach (415-gene signature) to
identify LPS-responsive eQTLs after 5-h LPS treatment in
dendritic cells and showed little overlap with both monocytes
works, which, however, can be explained by differences in
experimental design (Supplementary Fig. 9a and b). To discover
further immune-relevant eQTLs that might have been missed due
to limited power, we performed a replication analysis using data
from Fairfax et al.29 This led to the identiﬁcation of 672 cis and
237 trans additional iQTLs unique to TLR4 stimulation under
absolute expression and 222 cis and 79 trans additional iQTLs
under differential expression (Supplementary Fig. 9c and
Supplementary Data 3–5). Taken together, this demonstrates
the robustness of identifying immune-relevant eQTLs on LPS
stimulation.
In summary, eQTL studies in the context of cellular LPS
exposure provide comprehensive insights into the genetic
regulation of innate immunity. Among these, functional SNPs
for the expression of NEU4, CCL14, CBX3 and IRF5 contributed
strongest to interindividual differences in immune response.
Furthermore, we found that risk variants for PBC, IBD and celiac
disease exclusively regulate the expression of PDGFB and IL18R1
during immune response. Both genes are plausible candidates to
study the disease pathophysiology in context of immune
activation. Of course, follow-up studies on the biological function
of the here identiﬁed eQTLs will be essential to gain further
insights into the mechanisms of genetic variants regulating innate
immune responses.
Our study represents an innovative approach to gain insights
into gene–environmental interactions. The use of exogenous cell
stimulation followed by eQTL identiﬁcation might contribute to
the elucidation of the physiology and pathophysiology of many
cellular processes and diseases.
Methods
Sample collection, isolation and stimulation of CD14þ monocytes. In total,
185 healthy male volunteers of German descent were recruited. The study was
approved by the institutional review board of the University of Bonn. All volun-
teers signed informed consent and were between age 18 and 35 (mean 24). PBMC
were obtained by Ficoll-Hypaque density gradient centrifugation of heparinized
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Figure 5 | rs968451 and rs917997 represent the strongest GWAS-iQTL during TLR4 signalling. (a) PDGFB expression is allele-speciﬁcally induced on
LPS exposure, strongest for carriers of allele G. Violin plots are depicted as in Fig. 2. (b) Regional association plot from stimulated monocytes shows that
rs968451 regulates PDGFB expression selectively (red dot). In particular, MAP3K7IP1 expression is not allele-speciﬁcally inﬂuenced by rs968451 (green
dot). (c) In homozygous A carriers, IL18R1 expression is induced on LPS exposure and reduced in G carriers. Violin plots are depicted as in Fig. 2.
(d) Regional association plot from stimulated monocytes shows that rs917997 regulates IL18R1 expression strongest (red dot). In particular the expression
of genes belonging to the interleukin receptor cluster are not allele-speciﬁcally inﬂuenced by rs917997, although IL18RAP shows a tendency towards iQTL-
regulation (PLPS¼ 1.8 104, green dot).
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blood. Monocytes were isolated with anti-CD14 para-magnetic beads according to
the manufacturer’s manual (MACS, Miltenyi Biotec). The purity of isolated
monocytes was Z95%. RPMI 1640 (Biochrom) supplemented with 10% heat-
inactivated FCS (Invitrogen), 1.5mM L-glutamine, 100Uml 1 penicillin,
100mgml 1 streptomycin (all Sigma-Aldrich) and 10 ngml 1 GM-CSF (Immu-
noTools) was used to culture cells in 96-well round bottom wells at a density of
250,000 cells per well in 100 ml overnight. Cell survival after overnight incubation
was 485%. Cells of each volunteer were either untreated or treated with
200 ngml 1 ultrapure LPS from Escherichia coli (Invivogen). After 90min cells
were lysed in RLT reagent (Qiagen) and stored at  80 C. C-reactive protein
(CRP) levels were measured to exclude samples with elevated CRP levels. After
stringent quality control (Non-smoker, no infection or vaccination 4 weeks before
blood withdrawal, CRPo2.5mg dl 1, monocyte purityZ95%, monocyte survival
485%), ﬁnal samples from 137 individuals were further processed.
RNA extraction. RNA was extracted from the lysed cells using the AllPrep 96
DNA/RNA Kit from Qiagen. RNA concentrations were determined using Nano-
Drop (PeqLab) and a subset of samples was additionally checked for degradation in
a Bioanalyser (Agilent Technologies).
Gene expression analysis. The Illumina TotalPrep-96 RNA Ampliﬁcation Kit
(Life Technologies) was used for the ampliﬁcation and biotinylation of the RNA.
Subsequent array-based gene expression analysis was performed on Illumina’s
Human HT-12 v4 Expression BeadChips (Illumina) comprising 47,231 probes.
Expression proﬁles were normalized using function vsn2 implemented in the
Bioconductor package ‘vsn’31. Only probes that showed a Pdetectiono0.01 in more
than 5% of at least one of the two conditions (baseline, LPS) were analysed. Probes
that matched to multiple positions in the human genome and probes mapping to
non-autosomal chromosomes were excluded from further analysis. Finally, probes
were removed if SNPs within a probe showed an eQTL effect to the respective gene,
resulting in 17,684 probes for statistical analyses.
DNA extraction. Genomic DNA was extracted from 10ml blood using the Che-
magic Magnetic Separation Module I (PerkinElmer Chemagen) according to the
manufacturer’s instructions. DNA was quantiﬁed by NanoDrop (PeqLab).
DNA genotyping. Genotyping was conducted on the Illumina’s Huma-
nOmniExpress BeadChips comprising 730,525 SNPs. After quality control (PHWE
410–5, call rate 498%, MAF 45%), a total of 579,090 SNPs were available for
analysis. Samples showing potential admixture within the multi-dimensional
scaling analysis were removed. All samples showed a call rate 499%.
SNP imputation of GWAS ﬁndings. SNPs reported in previous GWAS and not
present on the HumanOmniExpress BeadChips were imputed. Imputation was
performed using IMPUTE2 (ref. 32) based on 1,000 Genomes Pilot I (European) as
a reference panel.
Pathway analysis. Data were evaluated using Ingenuity Pathway Analysis (IPA;
Ingenuity Systems, Redwood City, CA, USA). IPA maps each gene within a global
molecular network developed from information contained in the Ingenuity Pathways
Knowledge Base. Gene networks were generated algorithmically based on their
connectivity in terms of expression, activation and transcription. A ‘network’ in IPA
is deﬁned as a graphical representation of the molecular relationships between genes,
which are represented as nodes, and the biological relationship between nodes is
shown by a connecting line. All connections are supported by published data stored
in the Ingenuity Pathways Knowledge Base and/or PubMed33.
Pathway enrichment analysis of differentially expressed genes, clusters of co-
correlated genes and eQTL genes was performed using InnateDB34.
eQTL-analysis. Association tests were corrected for the top 10 multi-dimensional
scaling components. As phenotypes, we mapped absolute expression values of
untreated (PBaseline), LPS-treated (PLPS) and the differential expression of LPS-treated
monocytes (PDLPS/Baseline) separately. Association between SNP genotypes and gene
expression levels was examined by using a linear regression model of the phenotype
versus minor allele dosage of the genotype (additive model). All possible SNP/
phenotype combinations were tested exhaustively using PLINK v1.07 (ref. 35),
downstream analyses were carried out using R with appropriate packages and in-
house codes. cis-acting eQTLs were deﬁned as SNPs located within 1-Mb interval on
either side of a transcript to differentiate them from trans-acting eQTLs.
MANOVA implemented in R was used to map shared eQTLs between treated
and untreated monocytes, which is equivalent to the Bayesian formulation given in
a previous study7. PLPS and PBaseline from standard univariate analysis were
compared with PManova. This revealed 3,154 genome-wide signiﬁcant eQTLs
(corresponding to 690 genes) at PManovao1.76 10–09 with an FDR of 0.01 where
PManovaomin(PLPS, PBaseline) and PBaselineo8.67 10–09 and PLPSo7.35 10–09.
Replication of eQTLs. The study data set was compared with a recently published
eQTL data set under LPS stimulation29, which used the same Illumina HumanHT-
12 expression and HumanOmniExpress genotyping platform. We conducted a
replication analysis of peak cis eQTLs (6,509 eQTLs under baseline and 6,513
eQTLs on 2-h LPS stimulation) from Fairfax et al.29 This revealed (i) 1,731
additional cis eQTLs under baseline condition (corresponding to 1,092 genes;
PBaseline.ciso4.15 10 03, FDR of 0.01), (ii) 1,659 cis eQTLs on LPS stimulation
(corresponding to 1,083 genes; PLPS.ciso3.87 10 03, FDR of 0.01) and (iii) 222
cis iQTLs when fold change on LPS treatment is considered (corresponding to 161
genes; PDLPS/Baseline ciso3.5 10 04, FDR of 0.01). Testing trans eQTLs (4,354
eQTLs under baseline and 2,359 eQTLs on 2-h LPS stimulation) of the same study
revealed (iv) 1,671 additional trans eQTLs under baseline condition (corresponding
to 137 genes; PBaseline.transo5.82 10 03, FDR of 0.01), (v) 1,050 trans eQTLs on
LPS stimulation (corresponding to 109 genes; PLPS.transo7.32 10 03, FDR of
0.01) and (vi) 79 trans iQTLs when fold change on LPS treatment is considered
(corresponding to 14 genes; PDLPS/Baseline transo1.71 10 04, FDR of 0.01).
Replication analysis of PBaseline and PLPS were conducted on a per-condition basis
with identical effect directions, whereas for PDLPS/baseline the union of eQTLs under
baseline and LPS treatment was used. For the latter, we checked for identical effect
directions in both the treated and untreated conditions.
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